# Stage I/II Nasal NK Cell Lymphoma

> **NCT01321008** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **RADIATION:** Radiation
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01321008
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2015-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01321008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01321008, "Stage I/II Nasal NK Cell Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01321008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*